Boehringer Ingelheim, a MNC firm has obtained two separate interim injunctions against Dr Reddy’s and MSN Labs for selling their versions of Empagliflozin, an anti-diabetes drug in India. Both these pharma companies have recently launched a low-priced version of the anti-diabetes drug, Empagliflozin.
Highlights
- Boehringer Ingelheim obtains injunctions against Dr Reddy’s and MSN Labs....
Tags : Dr, Reddy’s, Patent, Diabetes, Pharma, Manufacturing, Boehringer Ingelheim,
comments (0)